SCHEMBL25408081

SCHEMBL25408081

Nc1sc(-c2cnn(C3COC3)c2)nc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 1/20 0.44
▸ ALOX5AP P20292 7/20 0.40
▸ JAK2 O60674 2/20 0.39
▸ PIK3CD O00329 1/20 0.38
▸ PIK3CA P42336 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PI4KA P42356 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ PI4KB Q9UBF8 1/20 0.38
▸ PIM1 P11309 1/20 0.37
▸ BMPR1A P36894 1/20 0.37
▸ ACVRL1 P37023 1/20 0.37
▸ ACVR1 Q04771 1/20 0.37
▸ LRRK2 Q5S007 1/20 0.35
▸ PAICS P22234 2/20 0.34
▸ BRD4 O60885 1/20 0.34
▸ CREBBP Q92793 1/20 0.34
▸ EIF4E P06730 1/20 0.34
▸ MKNK1 Q9BUB5 1/20 0.34
▸ MKNK2 Q9HBH9 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26847521 0.84 PIM1 (0.42) KITALOX5APJAK2PIK3CDPIK3CA
SCHEMBL25407249 0.70 ALOX5AP (0.35) KITALOX5APPIK3CDPIK3CAPI4KA
SCHEMBL2574462 0.68 KIT (0.48) KITALOX5APJAK2PIM1BMPR1A
SCHEMBL30291378 0.66 CCNE1 (0.46) KITALOX5APJAK2PIK3CAPIM1
SCHEMBL30919959 0.66 KIT (0.42) KITALOX5APJAK2PIM1BMPR1A
SCHEMBL25409694 0.65 BACE1 (0.44) ALOX5APJAK2PIK3CDPIK3CAPIK3CB
SCHEMBL16968072 0.64 TTK (0.50) KITJAK2PIM1BRD4EIF4E
SCHEMBL24956329 0.64 PIM1 (0.43) KITALOX5APJAK2PIM1BMPR1A
SCHEMBL28862512 0.64 KIT (0.48) KITALOX5APJAK2PIK3CDPIK3CA
SCHEMBL1951909 0.63 JAK2 (0.50) KITALOX5APJAK2PIK3CALRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4578451-A2 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2025-07-02 — — EP disclosed
EP-4214210-B1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS NOVARTIS AG (CH) 2025-04-09 — — EP disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS NOVARTIS AG (CH) 2023-11-16 — — US disclosed
CN-116615425-A Compounds and compositions as Sppl2a inhibitors 诺华股份有限公司 2023-08-18 — — CN disclosed
EP-4214210-A1 COMPOUNDS AND COMPOSITIONS AS SPPL2A INHIBITORS Novartis AG (CH) 2023-07-26 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365571-A1 COMPOUNDS AND COMPOSITIONS AS Sppl2a INHIBITORS SPPL2A, SPPL2B, BACE1 KIT 2015/4885ALOX5AP 3548/4885JAK2 3700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback